Entrada Therapeutics (TRDA) Change in Account Payables (2020 - 2026)
Entrada Therapeutics' (TRDA) quarterly Change in Account Payables came in at $641000.0 in Q1 2026, up 133.56% year-on-year from $274447.4 in Q1 2025, and up 173.09% quarter-over-quarter from -$877000.0 in Q4 2025.
Entrada Therapeutics (TRDA) Change in Account Payables (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at $641000.0 for Q1 2026.
- On a quarterly basis, Change in Account Payables rose 133.56% year-over-year to $641000.0 in Q1 2026; TTM through Mar 2026 was $752000.0, a 384.85% increase from a year earlier, with the FY2025 full-year figure at -$1.8 million, down 281.53% from the prior year.
- Change in Account Payables advanced to $641000.0 in Q1 2026 per TRDA's latest filing, from -$877000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $4.6 million in Q4 2022 and bottomed at -$4.4 million in Q2 2023.
- The 5-year median for Change in Account Payables is -$314000.0 (2024), against an average of $136176.5.
- Biggest YoY gain for Change in Account Payables was 869.03% in 2022; the steepest drop was 3733.75% in 2022.
- Year by year, Change in Account Payables stood at $4.6 million in 2022, then slumped by 47.62% to $2.4 million in 2023, then advanced by 18.29% to $2.8 million in 2024, then slumped by 130.82% to -$877000.0 in 2025, then soared by 173.09% to $641000.0 in 2026.
- Per Business Quant, the three latest TRDA Change in Account Payables figures stand at $641000.0 (Q1 2026), -$877000.0 (Q4 2025), and $1.3 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Entrada Therapeutics | 253.11 Mn | 253.11 Mn | - | 641,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 641,000.00 |
| Mar 31, 2026 | 641,000.00 |
| Dec 31, 2025 | -877,000.00 |
| Dec 31, 2025 | -877,000.00 |
| Sep 30, 2025 | 1.31 Mn |
| Sep 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | -321,000.00 |
| Jun 30, 2025 | -321,000.00 |
| Mar 31, 2025 | -1.91 Mn |
| Mar 31, 2025 | -1.91 Mn |
| Dec 31, 2024 | 2.85 Mn |
| Dec 31, 2024 | 2.85 Mn |
| Sep 30, 2024 | -314,000.00 |
| Sep 30, 2024 | -314,000.00 |
| Jun 30, 2024 | -886,000.00 |
| Jun 30, 2024 | -886,000.00 |
| Mar 31, 2024 | -655,000.00 |
| Mar 31, 2024 | -655,000.00 |
| Dec 31, 2023 | 2.41 Mn |
| Dec 31, 2023 | 2.41 Mn |